| Market Cap | 345.56M | P/E | - | EPS this Y | 13.60% | Ern Qtrly Grth | - |
| Income | -77.09M | Forward P/E | -3.85 | EPS next Y | 7.90% | 50D Avg Chg | -12.00% |
| Sales | 10.06M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -20.00% |
| Dividend | N/A | Price/Book | 2.39 | EPS next 5Y | - | 52W High Chg | -34.00% |
| Recommedations | 2.00 | Quick Ratio | 6.38 | Shares Outstanding | 188.78M | 52W Low Chg | 12.00% |
| Insider Own | 22.30% | ROA | -30.59% | Shares Float | 135.51M | Beta | 1.91 |
| Inst Own | 51.52% | ROE | -59.96% | Shares Shorted/Prior | 6.56M/6.64M | Price | 2.08 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 566,532 | Target Price | 5.00 |
| Oper. Margin | -1,238.24% | Earnings Date | Nov 5 | Volume | 483,415 | Change | -4.59% |
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Sims Karen | Chief Medical Office.. Chief Medical Officer | Feb 01 | Sell | 2.31 | 4,358 | 10,067 | 125,542 | 02/05/24 |
| HASTINGS DAVID C | Chief Financial Offi.. Chief Financial Officer | Feb 01 | Sell | 2.31 | 9,593 | 22,160 | 181,907 | 02/05/24 |
| Sofia Michael J. | Chief Scientific Off.. Chief Scientific Officer | Feb 01 | Sell | 2.31 | 9,982 | 23,058 | 1,485,121 | 02/05/24 |
| McElhaugh Michael J. | Interim President &.. Interim President & CEO | Feb 01 | Sell | 2.31 | 10,164 | 23,479 | 1,504,793 | 02/05/24 |
| McElhaugh Michael J. | Chief Business Offic.. Chief Business Officer | Dec 16 | Sell | 5 | 40,000 | 200,000 | 1,327,457 | 12/16/20 |